JP7112660B2 - 個別化医療における情報の電子配信 - Google Patents
個別化医療における情報の電子配信 Download PDFInfo
- Publication number
- JP7112660B2 JP7112660B2 JP2020546907A JP2020546907A JP7112660B2 JP 7112660 B2 JP7112660 B2 JP 7112660B2 JP 2020546907 A JP2020546907 A JP 2020546907A JP 2020546907 A JP2020546907 A JP 2020546907A JP 7112660 B2 JP7112660 B2 JP 7112660B2
- Authority
- JP
- Japan
- Prior art keywords
- data
- individual patient
- social network
- patient
- computer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title description 46
- 238000009826 distribution Methods 0.000 title description 5
- 238000004458 analytical method Methods 0.000 claims description 107
- 238000000034 method Methods 0.000 claims description 92
- 238000012360 testing method Methods 0.000 claims description 86
- 208000024827 Alzheimer disease Diseases 0.000 claims description 63
- 108700028369 Alleles Proteins 0.000 claims description 29
- 238000012384 transportation and delivery Methods 0.000 claims description 27
- 238000011338 personalized therapy Methods 0.000 claims description 26
- 239000000090 biomarker Substances 0.000 claims description 25
- 238000012216 screening Methods 0.000 claims description 25
- 238000003745 diagnosis Methods 0.000 claims description 20
- 230000036541 health Effects 0.000 claims description 20
- 238000011002 quantification Methods 0.000 claims description 18
- 102100024210 CD166 antigen Human genes 0.000 claims description 16
- 238000012544 monitoring process Methods 0.000 claims description 16
- 238000002560 therapeutic procedure Methods 0.000 claims description 16
- 210000004556 brain Anatomy 0.000 claims description 15
- 230000002068 genetic effect Effects 0.000 claims description 12
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 claims description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 10
- 238000010362 genome editing Methods 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 101000657452 Homo sapiens Rotatin Proteins 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102100035347 DmX-like protein 2 Human genes 0.000 claims description 7
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 7
- 101000804534 Homo sapiens DmX-like protein 2 Proteins 0.000 claims description 7
- 101000966403 Homo sapiens Dynein light chain 1, cytoplasmic Proteins 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000010801 machine learning Methods 0.000 claims description 6
- 238000011160 research Methods 0.000 claims description 6
- 102100040565 Dynein light chain 1, cytoplasmic Human genes 0.000 claims description 5
- 238000004422 calculation algorithm Methods 0.000 claims description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 102100034742 Rotatin Human genes 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 4
- 238000003012 network analysis Methods 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 102000013498 tau Proteins Human genes 0.000 claims description 4
- 108010026424 tau Proteins Proteins 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 3
- 238000010354 CRISPR gene editing Methods 0.000 claims description 3
- 238000013528 artificial neural network Methods 0.000 claims description 3
- 238000009534 blood test Methods 0.000 claims description 3
- 238000009593 lumbar puncture Methods 0.000 claims description 3
- 238000000053 physical method Methods 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 102210065456 rs157582 Human genes 0.000 claims description 3
- 102210001774 rs2075650 Human genes 0.000 claims description 3
- 102220419061 rs283815 Human genes 0.000 claims description 3
- 102220412564 rs34095326 Human genes 0.000 claims description 3
- 102210023165 rs4420638 Human genes 0.000 claims description 3
- 102210012590 rs56131196 Human genes 0.000 claims description 3
- 102220373983 rs71352238 Human genes 0.000 claims description 3
- 102210050807 rs75627662 Human genes 0.000 claims description 3
- 102210002368 rs769449 Human genes 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 101150014309 ALCAM gene Proteins 0.000 claims description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000007405 data analysis Methods 0.000 description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 201000010099 disease Diseases 0.000 description 28
- 238000002595 magnetic resonance imaging Methods 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- 230000001149 cognitive effect Effects 0.000 description 19
- 238000010586 diagram Methods 0.000 description 18
- 238000007726 management method Methods 0.000 description 18
- 238000003860 storage Methods 0.000 description 16
- 238000007481 next generation sequencing Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000004220 aggregation Methods 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000010191 image analysis Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 230000002452 interceptive effect Effects 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 8
- 238000002598 diffusion tensor imaging Methods 0.000 description 8
- 230000000971 hippocampal effect Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000003190 augmentative effect Effects 0.000 description 5
- 238000007418 data mining Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 206010072599 Amyloid related imaging abnormalities Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013481 data capture Methods 0.000 description 4
- 238000007435 diagnostic evaluation Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 4
- 238000012268 genome sequencing Methods 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000092 prognostic biomarker Substances 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 101150037123 APOE gene Proteins 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000006855 networking Effects 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- 108091005515 EGF module-containing mucin-like hormone receptors Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000013474 audit trail Methods 0.000 description 2
- 229940125385 biologic drug Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012517 data analytics Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 238000002079 electron magnetic resonance spectroscopy Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000011331 genomic analysis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 101150033186 Dynll1 gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000289247 Gloriosa baudii Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012896 Statistical algorithm Methods 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013503 de-identification Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000009808 hippocampal neurogenesis Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012978 minimally invasive surgical procedure Methods 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000003058 natural language processing Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 101150011693 phr gene Proteins 0.000 description 1
- 239000013259 porous coordination polymer Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000004984 smart glass Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/919,666 | 2018-03-13 | ||
| US15/919,666 US11089959B2 (en) | 2013-03-15 | 2018-03-13 | Electronic delivery of information in personalized medicine |
| PCT/US2019/021945 WO2019178167A1 (fr) | 2018-03-13 | 2019-03-12 | Distribution électronique d'informations dans un médicament personnalisé |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515940A JP2021515940A (ja) | 2021-06-24 |
| JP7112660B2 true JP7112660B2 (ja) | 2022-08-04 |
Family
ID=67906956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546907A Active JP7112660B2 (ja) | 2018-03-13 | 2019-03-12 | 個別化医療における情報の電子配信 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3764902A4 (fr) |
| JP (1) | JP7112660B2 (fr) |
| WO (1) | WO2019178167A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117136234A (zh) * | 2021-04-13 | 2023-11-28 | 国立大学法人京都大学 | 信息处理方法、信息处理装置以及程序 |
| CN113736860A (zh) * | 2021-09-10 | 2021-12-03 | 常州先趋医疗科技有限公司 | 基因快速筛查方法和装置 |
| KR102694387B1 (ko) * | 2023-11-28 | 2024-08-13 | 주식회사 지아이솔루션즈 | 의료 정보 인프라 구축 시스템 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014012007A (ja) | 2009-07-03 | 2014-01-23 | Univ College Cardiff Consultants Ltd | アルツハイマー病の診断および治療 |
| JP2014533949A (ja) | 2011-11-10 | 2014-12-18 | ジェネンテック， インコーポレイテッド | アルツハイマー病を治療、診断、および監視するための方法 |
| JP2015015010A (ja) | 2013-06-03 | 2015-01-22 | 株式会社日本エンブレース | 医療・介護支援方法、医療・介護支援システム及び医療・介護支援プログラム |
| US20150363553A1 (en) | 2013-06-18 | 2015-12-17 | Naryan L. Rustgi | Medical registry |
| JP2016517595A (ja) | 2013-03-15 | 2016-06-16 | アイ２ディーエックス インコーポレイテッド | 個別化医療における情報の電子配信 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006016085D1 (de) * | 2005-03-16 | 2010-09-23 | Genentech Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
| US7695911B2 (en) * | 2005-10-26 | 2010-04-13 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof |
| US20080176239A1 (en) * | 2007-01-19 | 2008-07-24 | Smithkline Beecham Corporation | Genes associated with schizophrenia |
| DK2773779T3 (da) * | 2011-11-04 | 2020-11-23 | Population Bio Inc | Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande |
-
2019
- 2019-03-12 JP JP2020546907A patent/JP7112660B2/ja active Active
- 2019-03-12 WO PCT/US2019/021945 patent/WO2019178167A1/fr unknown
- 2019-03-12 EP EP19767955.8A patent/EP3764902A4/fr active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014012007A (ja) | 2009-07-03 | 2014-01-23 | Univ College Cardiff Consultants Ltd | アルツハイマー病の診断および治療 |
| JP2014533949A (ja) | 2011-11-10 | 2014-12-18 | ジェネンテック， インコーポレイテッド | アルツハイマー病を治療、診断、および監視するための方法 |
| JP2016517595A (ja) | 2013-03-15 | 2016-06-16 | アイ２ディーエックス インコーポレイテッド | 個別化医療における情報の電子配信 |
| JP2015015010A (ja) | 2013-06-03 | 2015-01-22 | 株式会社日本エンブレース | 医療・介護支援方法、医療・介護支援システム及び医療・介護支援プログラム |
| US20150363553A1 (en) | 2013-06-18 | 2015-12-17 | Naryan L. Rustgi | Medical registry |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019178167A1 (fr) | 2019-09-19 |
| EP3764902A4 (fr) | 2021-12-08 |
| JP2021515940A (ja) | 2021-06-24 |
| EP3764902A1 (fr) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11419497B2 (en) | Electronic delivery of information in personalized medicine | |
| US20210338080A1 (en) | Alzheimer's disease personalized medicine | |
| Tresp et al. | Going digital: a survey on digitalization and large-scale data analytics in healthcare | |
| US20240038382A1 (en) | Methods of treatment and diagnosis using enhanced patient-physician communication | |
| US8788287B2 (en) | Systems, apparatus, and methods for developing patient medical history using hierarchical relationships | |
| US9208284B1 (en) | Medical professional application integration into electronic health record system | |
| CA2858355C (fr) | Systemes, procedes et supports pour des services de test en laboratoire | |
| US20110125527A1 (en) | Systems, apparatus, and methods for identifying patient-to patient relationships | |
| JP7112660B2 (ja) | 個別化医療における情報の電子配信 | |
| US20230110360A1 (en) | Systems and methods for access management and clustering of genomic, phenotype, and diagnostic data | |
| WO2018089875A2 (fr) | Architecture pour dossier de santé centrée sur une personne | |
| Al-Ahmadi et al. | Blockchain based remote patient monitoring system | |
| Collen et al. | Medical informatics: past and future | |
| US20240024417A1 (en) | Therapeutic modulation of alcam/cd166 | |
| US20220022749A1 (en) | Alzheimer's disease personalized medicine | |
| Chakraborty et al. | Healthcare data monitoring under Internet of Things | |
| Shahsavari et al. | Integration of Federated Learning and Blockchain in Healthcare: A Tutorial | |
| Koufi et al. | An EHR Platform for Realizing Precision Medicine in Emergency Care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201111 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211013 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220204 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220621 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220706 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7112660 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |